| Kyung Heup Ahn, MD | |
|
184 Liberty St, Yale Psychiatric Hospital, New Haven, CT 06519-1625 | |
| (203) 688-9907 | |
| Not Available |
| Full Name | Kyung Heup Ahn |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 28 Years |
| Location | 184 Liberty St, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750565016 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greenwich Hospital Association - | Greenwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greenwich Hospital | 3678476710 | 69 |
| Yale University | 9436061736 | 2241 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).
The California Association of Psychiatric Technicians is continuing a series of weekly informational pickets at state hospitals, developmental centers and prisons, this time – for the second time – at Napa State Hospital.
In a study of women with breast cancer, Kaiser Permanente researchers and others examined characteristics of women who refused recommended follow-up testing after a positive breast cancer screening test, or a visit to a medical provider for breast cancer symptoms.
BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).
› Verified 6 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).
The California Association of Psychiatric Technicians is continuing a series of weekly informational pickets at state hospitals, developmental centers and prisons, this time – for the second time – at Napa State Hospital.
In a study of women with breast cancer, Kaiser Permanente researchers and others examined characteristics of women who refused recommended follow-up testing after a positive breast cancer screening test, or a visit to a medical provider for breast cancer symptoms.
BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).
› Verified 6 days ago
| Entity Name | Greenwich Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609846088 PECOS PAC ID: 3678476710 Enrollment ID: O20040128000288 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).
The California Association of Psychiatric Technicians is continuing a series of weekly informational pickets at state hospitals, developmental centers and prisons, this time – for the second time – at Napa State Hospital.
In a study of women with breast cancer, Kaiser Permanente researchers and others examined characteristics of women who refused recommended follow-up testing after a positive breast cancer screening test, or a visit to a medical provider for breast cancer symptoms.
BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).
› Verified 6 days ago
| Entity Name | Yale New Haven Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336139500 PECOS PAC ID: 8325935018 Enrollment ID: O20040227000825 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).
The California Association of Psychiatric Technicians is continuing a series of weekly informational pickets at state hospitals, developmental centers and prisons, this time – for the second time – at Napa State Hospital.
In a study of women with breast cancer, Kaiser Permanente researchers and others examined characteristics of women who refused recommended follow-up testing after a positive breast cancer screening test, or a visit to a medical provider for breast cancer symptoms.
BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).
› Verified 6 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881629434 PECOS PAC ID: 8022915677 Enrollment ID: O20041227000221 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).
The California Association of Psychiatric Technicians is continuing a series of weekly informational pickets at state hospitals, developmental centers and prisons, this time – for the second time – at Napa State Hospital.
In a study of women with breast cancer, Kaiser Permanente researchers and others examined characteristics of women who refused recommended follow-up testing after a positive breast cancer screening test, or a visit to a medical provider for breast cancer symptoms.
BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyung Heup Ahn, MD 107 John St, Suite 3a, Southport, CT 06890-1466 Ph: (203) 429-4392 | Kyung Heup Ahn, MD 184 Liberty St, Yale Psychiatric Hospital, New Haven, CT 06519-1625 Ph: (203) 688-9907 |
News Archive
Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.
Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).
The California Association of Psychiatric Technicians is continuing a series of weekly informational pickets at state hospitals, developmental centers and prisons, this time – for the second time – at Napa State Hospital.
In a study of women with breast cancer, Kaiser Permanente researchers and others examined characteristics of women who refused recommended follow-up testing after a positive breast cancer screening test, or a visit to a medical provider for breast cancer symptoms.
BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).
› Verified 6 days ago
Sharon Hasbani, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 136 Sherman Ave, New Haven, CT 06511 Phone: 203-562-8071 | |
Dr. Jennifer Buenzle Dwyer, M.D., PH.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 20 York St # T-209, Yale-new Haven Hospital, New Haven, CT 06510 Phone: 203-433-2788 Fax: 203-688-5599 | |
Neeharika Thottempudi, MBBS Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Dr. Nancy Dian Olson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 47 Trumbull St, New Haven, CT 06510 Phone: 203-785-1898 Fax: 203-281-3707 | |
George J. Watstein, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 100 York St, Suite 2 A, New Haven, CT 06511 Phone: 203-624-6431 Fax: 203-624-6452 | |
Dr. Sidney Hornor Phillips, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 234 Church St, Suite #300, New Haven, CT 06510 Phone: 203-865-8246 | |
Dr. Marc D. Schwartz, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 26 Trumbull St, New Haven, CT 06511 Phone: 203-562-9873 Fax: 203-624-2422 |